References
- Ferguson A, Murray D. Quantitation of intraepithelial lymphocytes in human jejunum. Gut 107112:988–94.
References
- Farup PG, Bytzer P. Tegaserod: merely a laxative? Scand J Gastroenterol 2004;39:404–5.
- Nyhlin H, Bang C, Elsborg L, Silvennoinen J, Holme I, RUegg P, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004;39:119–26.
- Coehlo A-M, Rovira P, Fioramonti J, Bueno L. Antinociceptive properties of HTF 919 (tegaserod) a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology 2000; 118 Suppl 2:A835, 4393.
- Schikowski A, Thewissen M, Mathis C, Ross H-G, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastro- enterol Motil 2002;14: 221–7.
- Lacy BE, Yu S. Tegaserod. A new 5-HT4 agonist. J Clin Gastroenterol 2002;34: 27–33.
- Wei JY, Wang YH, Mayer E. The 5-HT4 receptor partial agonist, tegaserod, inhibits the colorectal distension-induced response in rat inferior splanchnic afferents in vitro. Gastroenterology 2002; Suppl 4:A317.
- Greenwood-Van Meerveld B, Zumo D, Crowell M. The importance of 5HT4-mediated mechanisms in the regulation of colonic hypersensitivity in rats. Gastroenterology 2003; 124 Suppl 1:A1.
- Dunger-Baldauf C, Ruegg P, Lefkowitz M. Is relief from abdominal pain/discomfort in tegaserod-treated IBS-C patients due to an increased frequency of bowel movements? Am J Gastroenterol 2002;Suppl:S275.
- Müller-Lissner SA, Talley NJ, Drossman D, Rueegg P, Dunger- Baldauf C, Shi Y, et al. Subject’s global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003;56:310–6.
- Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15: 1655–66.
- Lefkowitz M, Shi Y, Schmitt C, Krumholz S, Tanghe J. The 5- HT4 partial agonist, tegaserod, improves abdominal discomfort/ pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am J Gastroenterol 1999;94: 266.
- Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16: 1877–88.
- Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, et al. An Asia-Pacific, double blind, placebo-controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52:671–6.
- Tegaserod Clinical Research Group., A randomized, doubleblind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation- predominant irritable bowel syndrome. Zhonghua Nei Ke Za Zhi 2003;42:88–90.
- American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97:S1–5.
- Valenzuela J, Alvarado J, Cohen H, Damiao A, Francisconi C, Frugone L, et al. Latin-American consensus document on irritable bowel syndrome. Gastroenterol Hepatol 2004; 27:325–43.
- Talley NJ, Kamm MA, Müller-Lissner S, Tack J, Boeckzstaens G, Minushkin O, et al. Tegaserod is effective in relieving the multiple symptoms of constipation: results from a 12-week multinational study in patients with chronic constipation. Am J Gastroenterol 2003;98:S269–70.
- Johanson JF, Tougas G, Chey WD, Novick JS, Lembo A, Fordham F, et al. Tegaserod provides rapid and sustained relief of constipation, abdominal bloating/distension, and abdominal discomfort/pain in patients with chronic constipation. Gastroenterology 2003;124 Suppl 1:A47–8.